Iryo To Shakai
Online ISSN : 1883-4477
Print ISSN : 0916-9202
ISSN-L : 0916-9202
Research Article
Structural Analysis of Medical Resources Consumption in Ischemic-Heart-Disease Medical Treatment
A Trial Study on Resources Consumption of the Specific Medical Technology by Using Medical Receipt Information
Takuma Sugahara
Author information
JOURNAL FREE ACCESS

2002 Volume 13 Issue 3 Pages 3_15-3_43

Details
Abstract
In this paper, medical receipts (from June, 1993 to March, 1998) of "ischemic heart disease," including acute myocardial infarction and angina pectoris, were extracted through the full cooperation of a major electrical machinery company's health insurance society. After constructing a 310 sample data set by making 1 episode, from entering hospital to leaving, into 1 sample, descriptive analysis was performed from the perspectives of "patient characteristics attribute", "medical treatment and technology attribute" and "hospital characteristics attribute".
Next, in order to estimate the effect of each medical technology adoption on resources consumption more strictly, Cardiac Catheterization Inspection (CATH), Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary Artery Bypass Graft Surgery (CABG), Coronary Artery Stent (STENT), Thrombus Dissolution Agent Medication (THROMBOLYTICS) and Pacemaker Implantation (PACEMKR) were focused on as typical medical technology in Ischemic-Heart-Disease treatment. In the process of estimation of regression models, weighted least-squares method was performed while considering error-term distributed heterogeneity.
As a result of regression analysis on the "total medical examination point", it was suggested that application of PTCA was 76,000-77,000 points, CABG/about 270,000 points, THROMBOLYTICS/32,000-36,000 points, STENT/49,000-60,000 points and accommodation into ICU or CCU per one day/6,300-6,400 points respec-tively.
In the model, the explained variable "hospitalization period", marginal extension of hospitalization period by the application of PTCA, CABG, THROMBOLYTICS, and PACEMKR were 7-8 days, 12-14 days, 14-15 days and 6 to 9 days respectively. And in the case where acute myocardial infarction was the main disease, it was statistically confirmed that the hospitalization period would be extended by around 10 days compared with other disease cases. Furthermore, depending on the hospital characteristics, statistically significant differences were also acknowledged in the hospitalization period.
Content from these authors
© 2002 The Health Care Science Institute
Previous article Next article
feedback
Top